Home > Boards > US OTC > Miscellaneous > Kannalife Inc. (KLFE)

Dean14

As Well As 2

Posts 411

Boards Moderated

Alias Born 06/14/18

KLFE

Current Price

Volume:

KLFE Detailed Quote

Current Report Filing (8-k) Edgar (US Regulatory) - 3/18/2020 5: 05: 13 PM

Current Report Filing (8-k) Edgar (US Regulatory) - 1/28/2020 9: 01: 16 AM

Statement of Variations in Beneficial Ownership (4) Edgar (US Regulatory) - 12/3/2019 3: 47: 50 PM

Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 5: 16: 10 PM

Confidential Treatment Order (ct Order) Edgar (US Regulatory) - 8/14/2019 10: 52: 16 AM

Quarterly Report (10-q) Edgar (US Regulatory) - 8/13/2019 12: 48: 10 PM

Notice of Effectiveness (result) Edgar (US Regulatory) - 8/13/2019 6: 00: 43 AM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 8/8/2019 2: 07: 28 PM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 7/30/2019 11: 19: 33 AM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 7/5/2019 12: 18: 40 PM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 6/17/2019 1: 54: 14 PM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 5/23/2019 2: 53: 01 PM

Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2019 2: 13: 44 PM

Securities Registration Statement (s-1/a) Edgar (US Regulatory) - 4/9/2019 1: 52: 41 PM

Annual Report (10-k) Edgar (US Regulatory) - 4/9/2019 1: 49: 06 PM

Notification That Annual Report Will Likely Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 4/1/2019 3: 54: 58 PM

Dean14 Thursday, 01/23/20 09: 10: 12 AM

Re: None

Post # of 34

Medical Marijuana, Inc. Portfolio Investment Company Kannalife, Inc. Issues Update on Intellectual Property and Newly Acquired Patents

9: 00 AM ET 1/23/20 | Dow Jones

San Diego, Ca, Jan. 23, 2020 /PRNewswire/ – Medical Marijuana, Inc. (OTC: MJNA) (the “Company”), the initial-possibly publicly dealt marijuana organization in the states that launched the world's initial-at any time marijuana-derived nutraceutical merchandise, source and makes sequence, released today that its collection investment provider Kannalife, Inc. (“Kannalife”) (OTC: KLFE) just lately provided an update on its intellectual property revolving approximately its world wide WIPO/PCT Patent WO2015/106108A2 called “Novel Functionalized 1,3-Benzene Diols and also their Technique of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”).

“Our company is proud to get Kannalife within our expense collection since they are consistently reaching new milestones in researching cannabinoid therapeutics,” stated Medical Marijuana, Inc. CEO Dr. Stuart Titus. “The amount of study during this living space has risen greatly over the past 12 months however, there is nonetheless important growth to generally be created. It's motivating to check out Kannalife at the forefront of this.”

Ever since the filing of your PCT Patent in 2015, Kannalife has received patent endorsement within the pursuing areas: U.S. Patent 9,611,213 “Novel Functionalized 1,3-Benzene Diols along with their Method of Use for treating Hepatic Encephalopathy,” U.S. Patent 10,004,722 “Means for managing hepatic encephalopathy or perhaps a disease related to free significant mediate stress and oxidative anxiety with book functionalized 1,3-benzene diols,” Japanese Patent JP6486950B2 “Novel Functionalized 1,3-Benzene Diols along with their Way of Use for the treating of Hepatic Encephalopathy” and Russian Patent RU2676475C2 “Novel Functionalized 1,3-Benzene Diols as well as their Procedure for Use for managing Hepatic Encephalopathy.”

Additionally, Kannalife's application for patent coverage of the intellectual house has become approved in the European Union (EU), China, and Australia. The Organization is awaiting detect from India, Brazil and Canada for recognize of approval. The Business anticipates sales receipt of patent grants in the Modern australia, China and EU some time while in the 1st and second quarters of 2020.

“When we finally submitted our patent app for 'Novel Functionalized 1,3-Benzene Diols as well as their Method of Use for managing Hepatic Encephalopathy,' we chose the things we consider to generally be by far the most viable drug areas for relocating our substances into numerous studies,” mentioned Dean Petkanas, CEO of Kannalife. “The extra patents we have attained will help us achieve the objectives in further marketplaces.”

Currently, Kannalife's leading substance choice KLS-13019, a cannabidiol (CBD)-like molecule is looked into in pre-scientific studies for the prospective treatments for neuropathic pain. Through extensive tests, Kannalife has diagnosed a effective, non-opioid alternative to the frontline treatment of chemo-stimulated peripheral neuropathy (CIPN).

About Medical Marijuana, Inc.

Our company is a firm of firsts. Medical Marijuana, Inc. (MJNA) is a marijuana company with about three particular organization devices within the non-psychoactive cannabinoid room: a worldwide profile of cannabinoid-primarily based nutraceutical brand names driven by HempMeds and Kannaway a pioneer in sourcing the highest-top quality appropriate non-psychoactive marijuana items created from professional hemp in addition to a cannabinoid-centered specialized medical investigation and organic substance advancement industry directed by its internal R&D and clinical team together with its drug expense lovers and companies including AXIM Biotechnologies, Inc. and Kannalife, Inc. Medical Marijuana, Inc. was named a top CBD manufacturer by CNBC. Medical Marijuana, Inc. was the first provider to receive significant import makes it possible for for CBD products through the governing bodies of Brazil,Mexico and Argentina, and Paraguay which is a frontrunner in the roll-out of world-wide areas. Medical Marijuana, Inc.'s head office is in San Diego, California, and additional data is offered at OTCMarkets.com or at www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.'s business online video, click this link.

About KLS-13019

KLS-13019 is Kannalife's top rated proprietary investigational CBD-like system for your possible therapy of a selection of neurodegenerative and neuropathic ache diseases, starting with chemotherapy-caused peripheral neuropathy (CIPN). KLS-13019 is not evaluated or permitted for affected person use with the U.S. Food and Drug Administration (FDA) or any other health related ability across the world. Its efficacy and security have not been verified by FDA-accredited investigation.

About Kannalife, Inc.

Family Office - A.D. Financial Sdn. Bhd.www.adfinancial.com.my › services › family-office A family office is dedicated to providing families with centralised support in managing their wealth to enable it to endure over several generations. What is a Family …

Kannalife, Inc. is actually a biopharmaceutical firm focused entirely on the growth of proprietary and patented cannabidiol (CBD) and CBD-like substances for affected individuals suffering from unmet healthcare desires of neurodegenerative ailments - which includes chemo-stimulated peripheral neuropathy (CIPN), a chronic neuropathy due to hazardous chemotherapeutic substances hepatic encephalopathy (HE), a neurotoxic mental faculties-liver organ disorder due to extreme concentrations of ethanol and ammonia inside the human brain light disturbing mental faculties injuries (mTBI), a disorder related to single and recurrent impression accidents and chronic distressing encephalopathy (CTE) a health problem affiliated with really recurring impression injuries in qualified and beginner athletics.

The Company's group of amazing substances targets curing oxidative tension-associated ailments including HE, persistent soreness from neuropathies like CIPN, and neurodegenerative disorders like CTE. Kannalife conducts its creation and investigation attempts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

FORWARD-LOOKING DISCLAIMER

(Image: https://images.template.net/10433/Private-Equity-Investment-Proposal.jpg)This press discharge might have specific frontward-appearing records and information, as outlined throughout the meaning of Section 27A with the Securities Act of 1933 and Section 21E with the Securities Exchange Act of 1934, and it is susceptible to the Safe Harbor developed by all those areas. This material has claims about envisioned long term functions and/or financial benefits which might be in front-shopping in subject and nature to uncertainties and potential risks. Such onward-looking documents by definition call for uncertainties, risks along with other variables, which can make the specific benefits, effectiveness or private equity achievements of Medical Marijuana, Inc. to always be materially completely different from the statements manufactured herein.

FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE

These assertions have not been analyzed by the Food and Drug Administration. This device is not really created to detect, get rid of and deal with or avert any condition.